10-Q: Syndax Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

Syndax Pharmaceuticals reports a net loss of $140.5 million for the first half of 2024, while advancing its clinical programs for revumenib and axatilimab.

Summary

• Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, reported a net loss of $140.5 million for the six months ended June 30, 2024, compared to a net loss of $85.7 million for the same period in 2023.
• The company's revenue for the first half of 2024 was $3.5 million, derived from milestone payments related to the approval of entinostat in China.
• Research and development expenses increased to $105.1 million for the first half of 2024, up from $68.8 million in the same period of 2023, driven by increased clinical trial activities and manufacturing expenses.
• Selling, general, and administrative expenses also rose to $52.1 million for the first half of 2024, compared to $26.9 million in the first half of 2023, due to commercial readiness activities and increased personnel costs.
• As of June 30, 2024, Syndax had cash, cash equivalents, and shortand long-term investments totaling $454.6 million.
• The company's New Drug Application (NDA) for revumenib is under review by the FDA, with a PDUFA target action date extended to December 26, 2024.
• The Biologics License Application (BLA) for axatilimab is also under FDA review, with a PDUFA action date of August 28, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical development and regulatory submissions, the significant increase in net loss and the delay in the revumenib NDA review temper the positive aspects. The company's strong cash position provides some reassurance, but the overall sentiment is neutral to slightly negative.

Positives

• Syndax achieved a $3.5 million milestone payment related to the approval of entinostat in China.
• The company has a strong cash position of $454.6 million, which is expected to fund operations for at least the next 12 months.
• Both the revumenib NDA and axatilimab BLA are under priority review by the FDA.
• Positive data from the BEAT AML trial showed a 96% composite complete remission rate in patients with newly diagnosed mNPM1 or KMT2Ar AML.
• The company is advancing multiple Phase 1 combination trials of revumenib in acute leukemias.

Negatives

• The company experienced a significant net loss of $140.5 million for the first half of 2024.
• Research and development expenses increased substantially to $105.1 million for the first half of 2024.
• Selling, general, and administrative expenses also increased significantly to $52.1 million for the first half of 2024.
• The PDUFA target action date for the revumenib NDA was extended to December 26, 2024.

Risks

• The company is subject to risks associated with obtaining regulatory approval for its product candidates.
• There are risks related to the commercial success of the product candidates, even if approved.
• The company relies on third-party suppliers and Incyte for manufacturing and distribution.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company may require additional capital to finance its operations, which may not be available on acceptable terms.
• The company is subject to risks related to intellectual property protection and potential litigation.
• The company is subject to risks related to data privacy and security.

Future Outlook

The company expects to report topline data from the AUGMENT-101 pivotal trial cohort of patients with R/R mNPM1 AML in the fourth quarter of 2024 and plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024. Incyte plans to initiate two combination trials with axatilimab in earlier lines of treatment for chronic GVHD in the second half of 2024.

Management Comments

• The company is focused on advancing its clinical programs for revumenib and axatilimab.
• The company is preparing for potential commercial launches of both revumenib and axatilimab.
• The company believes its cash position is sufficient to fund operations for at least the next 12 months.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on oncology and rare diseases. The company's progress with revumenib and axatilimab is being closely watched by investors and competitors alike. The company is also navigating the challenges of the current economic environment, including inflation and potential recession risks.

Comparison to Industry Standards

• Syndax's increased R&D spending is typical for a clinical-stage biotech company advancing multiple drug candidates.
• The company's cash burn rate is consistent with other companies in the sector, given the costs associated with clinical trials and pre-commercialization activities.
• The company's reliance on third-party manufacturers is a common practice in the biopharmaceutical industry.
• The company's collaboration with Incyte is similar to other partnerships in the industry, where companies share development and commercialization costs and risks.
• The company's focus on specific cancer subtypes (KMT2Ar and NPM1 mutant AML) is a trend in precision medicine, targeting niche patient populations.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the delay in the revumenib NDA review.
• Employees may be affected by the company's financial performance and any potential restructuring or cost-cutting measures.
• Patients may benefit from the potential approval of new treatments for cancer and fibrotic diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will report topline data from the AUGMENT-101 pivotal trial cohort of patients with R/R mNPM1 AML in the fourth quarter of 2024.
• The company plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.
• Incyte plans to initiate two combination trials with axatilimab in earlier lines of treatment for chronic GVHD in the second half of 2024.

Key Dates

Keywords

revumenib, axatilimab, clinical trials, FDA, regulatory approval, oncology, leukemia, graft-versus-host disease, biopharmaceutical, financial results